COVID patients with poor prognosis have significantly lower serum levels of vitamin D compared to those with good prognosis, according to new data from a systematic review that pulled data from seven previous studies into its meta analysis. A total of 1,368 COVID-19 patients were included in the pooled results. Those with poor prognosis had…
What do you think is going on here? The main report is that the death counts lag behind infection rates. But the pandemic (I like the term “patchwork pandemic”) has been raging through Florida, Arizona and Texas for quite some time now. Are we looking at a less lethal SARS CoV-2? It would appear so.…
It’s an understandable concern based on past experiences with other viral infections, such as influenza and measles, where children are known to be significant transmitters. However, according to several recent publications, infected children are less significant spreaders of COVID-19 and their own source of infection may more likey be symptomatic or pre-symptomatic adults. Adults who…
COVID-19 outcome disparities are rapidly becoming apparent for people with obesity and multiple black, Asian, and minority ethnic (BAME) groups.
In reference to the article: Quercetin: New Hype for COVID-19? We appreciate MPT’s reference to our phases paper and quote of Sam Yanuck, as well as their mention of the East Virginia Med School work. But there are more human clinical trials than the pharma PhDs suggest, which demonstrates bioavailability and efficacy. As…
Protective antibodies against COVID-19 may only last a short time after infection, new evidence shows. However, it doesn’t mean that scientists have definitively answered the question about lasting immunity for this particular virus. The current thinking is that even low levels of powerful neutralizing antibodies may still be protective – after all, the immune system…
COVID19 is upon us. Months earlier, we scheduled James Maskell to discuss his recent book: The Community Cure. Amazingly, his message today is all the more urgent. James argues for the group visit model, was an early adopter and proponent of group visits (in fact, we discuss the pre-publication Cleveland Clinic group visit research findings, which are astonishingly good; even better than the first JAMA publication comparing functional medicine one-on-one with family medicine.) Now, with COVID19 and self-isolation, the virtual visit and the virtual group visit (where James saw FxMed eventually going) is upon us. And specifically, his vision is that this model works in insurance- and even Medicare. James’ message – the promise of functional medicine – is timely, inspiring and essential. ~DrKF
This quote from The Scientist, in reference to the three preprint papers below: “They found that people with blood type A were at a higher risk for respiratory failure, while blood group O seemed to be protective. The odds for those with blood type A to be hospitalized with severe respiratory symptoms were nearly 1.5…
My research and analysis on the important connections between furin and SARS CoV-2 has been accepted as a preprint article on SSRN. Thank you, David Riley, for making that happen! Abstract: Furin is a protease that is ubiquitous in the mammalian metabolism. One of the innovations that make SARS-CoV-2 more infectious than its ancestor viruses…
More validation is emerging for the furin protease (“furin”) hypothesis I posited in this blog: The Furin Protease Connection: From SARS CoV-2 and Anthrax, to Diabetes and Hypertension and that is now available as a pre-print publication here. Considering furin protease inhibitors Scientists are validating furin inhibition as a possible pathway to addressing COVID. And in this Medical News Today…
